A patent application for a key aids drug in India recently provoked a written protest to the Delhi patent office on May 9, 2006, by the Indian Network for People Living with hiv/aids and the Delhi Network of Positive People. It was followed by a protest march the next day in Delhi.
Gilead Sciences had submitted a patent application for tenofovir disoproxil fumarate (tdf), a key aids drug, at the patent office in Delhi in 1998. With the Indian Patents Act 1970 being amended last year, the patent office has started examining thousands of patent application. The amendment constrains the production of generic versions of patented drugs through reverse engineering but also opens the possibility of raising objections against a patent before it is granted.
|
We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.
.png)
Comments are moderated and will be published only after the site moderator’s approval. Please use a genuine email ID and provide your name. Selected comments may also be used in the ‘Letters’ section of the Down To Earth print edition.